Marisa Woutersen

Key details

Marisa Woutersen is a senior reporter for Life Sciences Intellectual Property Review and World IP Review. She largely covers intellectual property developments across the global life sciences sector, including pharmaceuticals, biotechnology, medtech, AI, M&A and regulation.

Since joining Newton Media in 2023, Marisa has reported across a wide range of topics, from the rise of generative AI and its impact on the creative industries to the crossover between intellectual property and sport, including issues affecting athletes, as well as global pharmaceutical disputes, vaccine technology, access to medicines and life sciences M&A.

She has reported live from court and regularly travels to international conferences, where she interviews lawyers, business leaders and other key industry figures.

Marisa holds a Master’s in International Law and a BA in Politics and International Relations from the University of Sussex, and is currently completing her NCTJ Diploma in Journalism.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 456

Articles by Marisa Woutersen

AI, anxiety, and antibodies: The issues dominating life sciences
Americas
Two days of discussions at LSPN North America revealed an industry grappling with narrower patent claims, global strategy changes, AI disruption and tougher dealmaking conditions.   26 May 2026
Lupin scores another win in kidney drug dispute
Americas
A US appeals court has handed the generic drugmaker victory in a closely watched dispute over a treatment for a serious inherited kidney condition, dealing a setback to its branded rival.   22 May 2026
Chinese medtech company fined by UPC over injunction breaches
Europe
The court has imposed a financial penalty after finding it continued promoting banned devices online despite an injunction covering five European countries.   21 May 2026
Asia
Backed by the country’s wider AI ambitions, Google has signed a deal to roll out healthcare, scientific research, and safety initiatives.   20 May 2026
Americas
The firm brings in a former VP at a biotech company, with biologics experience across antibodies, antibody drug-conjugates, peptides and gene and cell therapies.   20 May 2026
Americas
In the firm’s second IP conflict dispute in a year, a healthcare tech company claims Kirkland lawyers "committed the cardinal sin of trying to represent the conflicting interests of opposing parties".   19 May 2026
Europe
A high-profile Paris-based partner and four others join the firm, bringing experience across M&A, venture capital and life sciences-focused transactions.   18 May 2026
Americas
A US court has refused to throw out AbbVie's claim that a former scientist brought its cancer drug secrets to a Chinese rival.   18 May 2026
Europe
Experts from Johnson & Johnson and Novartis took the stage at INTA to share the pitfalls lurking inside mergers, acquisitions and spin-offs and what in-house counsel can do about them.   7 May 2026
Europe
Panellists at INTA share how workplaces can bridge generational divides and why those differences may be a team’s biggest strengths.   6 May 2026

Not finding what you're looking for, please try resetting your applied search and filters,
or try the
full site search.